NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE48153 Query DataSets for GSE48153
Status Public on Nov 21, 2013
Title Protein Array Screening of Myelodysplastic Syndromes I
Platform organism Homo sapiens
Sample organisms Homo sapiens; unidentified
Experiment type Protein profiling by protein array
Summary In a two-stage study we investigated levels of Immunoglobulin G (IgG) reactivity in plasma from Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) post MDS patients (59 and 16 cases respectively) as compared to healthy cohort (34). In Stage I we utilized high-throughput protein arrays (23 232 total signals, in duplicate) to identify proteins of high-interest. In Stage II we designed new protein arrays (352 total signals, in duplicate) to further focus on 25 of the proteins from Stage I and expanded to a larger cohort, including both male and female samples (161 MDS and 43 AML patients; 112 healthy controls). Stage I resulted in 35 proteins displaying increased IgG reactivity in patients as compared to the healthy controls (P< 4.3 x10-07, Bonferroni Corrected P<0.01). This protein subset included 14 proteins associated with cancer, 12 with apoptosis, and 3 with the NFAT Regulation canonical pathway. Using the focused arrays we performed a classification of MDS patients and healthy controls. Stage II subsequently identified a high-interest focused set of 3 proteins, namely AKT3, FCGR3A and ARL8B displaying aberrant increased reactivity in patient subgroups, in concordance with Stage I. Autoantibody reactivity against specific proteins provides complementary information to other known molecular signatures for MDS and may enhance our capabilities for detecting and classifying MDS.
In the study presented here, MDS patients were classified into Stable, Transforming or AML post MDS (L) classes retrospectively. The different patients were compared to a healthy cohort to assess increased autoantibody reactivity to specific patients as opposed to healthy groups
 
Overall design Stage 1 of Study: 111 Files Analyzed, 37 sMDS, 22 tMDS, 16 AML(L), 34 Healthy and 2 Negative Controls (used to eliminate non-plasma signals)
 
Contributor(s) Mias GI, Chen R, Snyder M, Greenberg P
Citation(s) 24264604
Submission date Jun 20, 2013
Last update date Feb 20, 2014
Contact name George Mias
Organization name Michigan State University
Department Biochemistry and Molecular Biology
Street address 775 Woodlot Drive, Rm1319
City East Lansing
ZIP/Postal code 48824
Country USA
 
Platforms (1)
GPL14689 Invitrogen ProtoArray v5.0 (full array layout)
Samples (111)
GSM1170745 Patient N01 Sample
GSM1170746 Patient N02 Sample
GSM1170747 Patient N03 Sample
This SubSeries is part of SuperSeries:
GSE48155 Protein Array Screening of Myelodysplastic Syndromes
Relations
BioProject PRJNA209054

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE48153_RAW.tar 293.5 Mb (http)(custom) TAR (of GPR)
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap